Results 71 to 80 of about 80,546 (217)

T Cell Microenvironmental Impacts and Therapeutic Opportunities: Application to Human Testicular Germ Cell Tumors

open access: yesAndrology, EarlyView.
ABSTRACT Testicular germ cell tumors (TGCT) are the leading malignancy in adolescent and young adult males, yet the immunological and cellular mechanisms governing their tumor microenvironment (TME) remain poorly understood. Here, we present a comprehensive review of TGCT pathobiology with a focus on the immune landscape, particularly the role of tumor‐
R Islam   +7 more
wiley   +1 more source

Cesni‐cel (ARI0002h) in ultra‐high‐risk multiple myeloma with plasma cell leukaemia or central nervous system involvement

open access: yesBritish Journal of Haematology, EarlyView.
ARI0002h induced response in 15/17 patients with plasma cell leukaemia (PCL)/central nervous system (CNS)‐multiple myeloma (MM) (87% achieved ≥ very good partial response [VGPR]) with a median progression‐free survival (PFS)/overall survival (OS) of 10.5 and 15.9 months respectively.
Carlos Jimenez‐Mira   +25 more
wiley   +1 more source

Tn Antigen Expression Defines an Immune Cold Subset of Mismatch-Repair Deficient Colorectal Cancer. [PDF]

open access: yesInt J Mol Sci, 2020
Matsumoto T   +18 more
europepmc   +1 more source

Effects of chronic lymphocytic leukaemia (CLL)‐directed therapy on diffuse large B‐cell lymphoma (DLBCL) type Richter transformation compared to de novo DLBCL in a nationwide cohort

open access: yesBritish Journal of Haematology, EarlyView.
Summary Diffuse large B‐cell lymphoma (DLBCL) type Richter transformation (DLBCL‐RT) in patients with chronic lymphocytic leukaemia (CLL) has a worse prognosis compared to de novo DLBCL (dnDLBCL). We investigated outcomes of patients with DLBCL‐RT with or without previous CLL‐directed therapy compared to dnDLBCL between 2002 and 2022.
Andreas Katsimigas   +9 more
wiley   +1 more source

Adjusted delivery, stronger outcomes: Selinexor therapeutic adaptation and positioning in previously treated multiple myeloma

open access: yesBritish Journal of Haematology, EarlyView.
In patients with lenalidomide‐refractory multiple myeloma from the BOSTON trial subgroup analysis,1 selinexor (SEL) dose reduction versus full dosing substantially improved efficacy outcomes, including higher overall response rate (74.3% vs. 55.6%), deeper responses (≥ very good partial response: 48.6% vs.
Muhamed Baljevic
wiley   +1 more source

Tn Antigen Expression Contributes to an Immune Suppressive Microenvironment and Drives Tumor Growth in Colorectal Cancer. [PDF]

open access: yesFront Oncol, 2020
Cornelissen LAM   +7 more
europepmc   +1 more source

Intermediate clinical endpoints as surrogates for overall survival after salvage prostatectomy

open access: yesBJU International, EarlyView.
Objectives To evaluate biochemical recurrence‐free survival (BRFS) and metastasis‐free survival (MFS) as potential intermediate clinical endpoints (ICEs) for overall survival (OS) in patients undergoing salvage radical prostatectomy (sRP). Patients and Methods Evaluable patients were selected from a retrospective dataset, resulting in a cohort of 879 ...
Navid Roessler   +22 more
wiley   +1 more source

Home - About - Disclaimer - Privacy